June 19, 2024
Human Microbiome Market

The Growth Of The Human Microbiome Market Is Driven By Rising Awareness About Gut Health

The global human microbiome market is primarily driven by the rising awareness about gut health and its role in overall well-being. The human microbiome refers to the ecosystem of microorganisms such as bacteria, viruses, and fungi that live in association with the human body, especially in the gut. Probiotic supplements containing live microorganisms have proven benefits in maintaining a healthy gut microbiota and improving digestion. They help enhance the immune system and manage symptoms of various health conditions like irritable bowel syndrome, diarrhea, allergy, and eczema. Microbiome therapeutics targets specific microbial species or molecules to treat diseases beyond gastrointestinal issues. The growing acceptance of preventive healthcare and efforts to develop personalized medicines are supporting research on modulating the gut microbiome.

The global Human Microbiome Market is estimated to be valued at US$ 4248.55 Mn in 2023 and is expected to exhibit a CAGR of 24.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

One of the major trends in the human microbiome market is the increasing focus on developing microbiome-based therapies. Various companies are conducting clinical trials to evaluate microbiome-based therapies for various diseases like Clostridium difficile infection, inflammatory bowel disease, metabolic disorders, and cancer. For instance, Seres Therapeutics is evaluating SER-109, a microbiome therapeutic candidate, in a phase 3 clinical trial for recurrent C. difficile infection. BiomX is evaluating BX001 in a phase 2 trial for psoriasis. Such ongoing clinical research aims to validate the therapeutic potential of microbiome intervention in specific diseases beyond gastrointestinal issues. This is expected to promote the clinical acceptance and commercialization of microbiome-based approaches.

Porter’s Analysis

Threat of new entrants: The human microbiome market faces low threat from new entrants due to high R&D costs involved in novel drug discovery and clinical trials.

Bargaining power of buyers: The bargaining power of buyers is moderate given the availability of alternative probiotic supplements and lack of product differentiation.

Bargaining power of suppliers: A few global players dominate the raw material supply chain, giving them significant influence over pricing.

Threat of new substitutes: Potential threat from gut health-focused nutraceuticals and dietary supplements.

Competitive rivalry: Intense competition among existing players to gain first-mover advantage in developing novel microbiome-based therapies.

Key Takeaways

The Global Human Microbiome Market Demand  is expected to witness high growth over the forecast period. Regionally, North America is expected to dominate the market owing to increasing R&D investments and rising prevalence of lifestyle diseases. Europe is also projected to account for a significant share in the market driven by favorable regulatory approvals for microbiome-based therapies.

Regional analysis: North America is projected to be the largest as well as the fastest growing regional market for human microbiome over the forecast period. The growth can be attributed to increasing funding towards research projects, advanced healthcare infrastructure, and rising prevalence of chronic diseases in the region.

Key players: Key players operating in the human microbiome market include Seres Therapeutics, Biomesense, Microbiotica, Infant Bacterial Therapeutics AB, Vedanta Biosciences, Inc., Second genome therapeutics, 4D Pharma Ferring Inc, Enterome, BiomX, MaaT Pharma, Azitra, Illumina, Inc, Locus Biosciences, Inc, Finch Therapeutics Group, Inc, Rebiotix Inc, Servatus Ltd, Microbiome Research Pvt. Ltd, AOBiome, Axial Therapeutics, Inc.

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it